There is indeed good reason why the liquid biopsy is considered “liquid gold” and is therefore deserving all the attention it’s getting. Tycho Peterson, an analyst at J.P. Morgan, estimates the global testing market to reach $20 billion by 2020, $10 billion of which is estimated for use of DNA blood tests for cancer screening alone (estimated by Cowen & Co).
The development of technologies that allow the detection of circulating tumor cells, cell free DNA, or exosomes, combined with the advancements of sequencing technologies and the identification of novel biomarkers now allow more accurate detection and possible insights into the characteristics of malignant tumors than traditional biopsies (e.g. immunohistochemistry pathology type tests and/or tumor marker immunoassays). Liquid biopsy enables the detection of circulating tumor DNA in healthy individuals that are at high risk for cancer, the monitoring of patients with active or previously diagnosed cancer for risk of recurrence, or the detection of a molecular target or marker that may be indicative of a high probability of response to a specific treatment. This dynamic field is undergoing significant growth with many new startups as well as major companies taking up the challenge of commercializing and offering liquid biopsy products and services to the market.
At the 10th Personalized Medicine World Conference (PMWC) Silicon Valley, we have four sessions dedicated to liquid biopsy: Liquid Biopsy – A Game Changer, Non-Invasive Liquid Biopsies for Cancer Patients,Commercial Applications in Liquid Biopsy, and Liquid Biopsy: The Right Tool for the Right Job. This is a great opportunity to delve into this hot and evolving field, learn first-hand the latest advances, meet the opinion leaders and companies actively developing and commercializing products in the space, and hear about successful applications that will shape the evolution of healthcare.
Filed under: Inside BIO Industry Analysis,